Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor–Expressing Glutamatergic Neurons - PMC

Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor–Expressing Glutamatergic Neurons - PMC
Official websites use .gov
.gov
website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
lock
) or
means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Journal List
User Guide
PERMALINK
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
the contents by NLM or the National Institutes of Health.
Learn more:
PMC Disclaimer
PMC Copyright Notice
. 2018 May 18;67(8):1538–1548. doi:
10.2337/db17-1385
Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor–Expressing Glutamatergic Neurons
Jessica M Adams
Jessica M Adams
Department of Pediatrics, University of Michigan, Ann Arbor, MI
Find articles by
Jessica M Adams
Hongjuan Pei
Hongjuan Pei
Department of Pediatrics, University of Michigan, Ann Arbor, MI
Find articles by
Hongjuan Pei
Darleen A Sandoval
Darleen A Sandoval
Department of Surgery, University of Michigan, Ann Arbor, MI
Find articles by
Darleen A Sandoval
Randy J Seeley
Randy J Seeley
Department of Surgery, University of Michigan, Ann Arbor, MI
Find articles by
Randy J Seeley
Rui B Chang
Rui B Chang
Department of Cell Biology, Harvard Medical School, Boston, MA
Find articles by
Rui B Chang
Stephen D Liberles
Stephen D Liberles
Department of Cell Biology, Harvard Medical School, Boston, MA
Find articles by
Stephen D Liberles
David P Olson
David P Olson
Department of Pediatrics, University of Michigan, Ann Arbor, MI
Find articles by
David P Olson
1,
Department of Pediatrics, University of Michigan, Ann Arbor, MI
Department of Surgery, University of Michigan, Ann Arbor, MI
Department of Cell Biology, Harvard Medical School, Boston, MA
Corresponding author: David P. Olson,
dpolson@med.umich.edu
Received 2017 Nov 15; Accepted 2018 May 6; Issue date 2018 Aug.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at
PMC Copyright notice
PMCID: PMC6054439  PMID:
29776968
Abstract
Glucagon-like peptide 1 receptor (GLP-1R) agonists are U.S. Food and Drug Administration–approved weight loss drugs. Despite their widespread use, the sites of action through which GLP-1R agonists (GLP1RAs) affect appetite and body weight are still not fully understood. We determined whether GLP-1Rs in either GABAergic or glutamatergic neurons are necessary for the short- and long-term effects of the GLP1RA liraglutide on food intake, visceral illness, body weight, and neural network activation. We found that mice lacking GLP-1Rs in
vGAT
-expressing GABAergic neurons responded identically to controls in all parameters measured, whereas deletion of GLP-1Rs in
vGlut2
-expressing glutamatergic neurons eliminated liraglutide-induced weight loss and visceral illness and severely attenuated its effects on feeding. Concomitantly, deletion of GLP-1Rs from glutamatergic neurons completely abolished the neural network activation observed after liraglutide administration. We conclude that liraglutide activates a dispersed but discrete neural network to mediate its physiological effects and that these effects require GLP-1R expression on glutamatergic but not GABAergic neurons.
Introduction
The incretin glucagon-like peptide 1 (GLP-1) is produced mainly in intestinal L cells and a discrete population of hindbrain neurons. GLP-1 is released from the intestine after a meal and acts through its receptor (GLP-1R) to increase insulin and decrease glucagon secretion in a glucose-dependent manner (
). As such, long-acting synthetic GLP-1R agonists (GLP1RAs) are useful therapeutic agents to treat type 2 diabetes (
). Of note, long-acting GLP1RAs, such as liraglutide, not only improve blood glucose homeostasis but also cause significant weight loss (
). In rodents and humans, the weight loss is associated with a reduction in food intake with little effect on energy expenditure (
). Despite these clinically significant effects on body weight, the cellular mechanisms by which GLP1RAs modulate feeding are unclear, and understanding these mechanisms remains an important research goal.
GLP-1R is expressed in the pancreas, heart, kidney, gastrointestinal tract, and brain (
). We and others have shown that GLP-1R–expressing cells in the central nervous system (CNS) are required for the full anorectic and body weight effects of peripherally administered liraglutide in both mice and rats (
). GLP-1Rs are distributed across the CNS, including in areas known to be critical for the regulation of food intake and body weight (
). The fact that local microinfusion of GLP1RAs into numerous CNS nuclei is sufficient to decrease food intake (
10
) suggests that many GLP-1R–expressing neuronal populations contribute to the anorectic effects of peripherally administered liraglutide. To date, genetic deletion of GLP-1R from specific brain nuclei known to be involved in energy balance has shown that GLP-1Rs in the paraventricular hypothalamus (PVH), arcuate nucleus, and ventromedial nucleus of the hypothalamus are not necessary for the anorectic effects of peripherally administered GLP1RAs (
11
13
).
These results are consistent with a model in which the anorectic effects of GLP1RAs are distributed across the CNS rather than contained in a single anatomic site (
10
). Because cell-specific targeting of GLP-1R expression has yet to identify critical neural populations required for GLP1RA action, we used established neuron-specific Cre lines to target broad and mostly nonoverlapping neuronal populations:
vGlut2
-expressing glutamatergic and
vGAT
-expressing GABAergic neurons (
14
). With the use of Cre-dependent reporter animals, we examined and cataloged the brain regions and neuronal subtypes activated by liraglutide and found a discrete pattern of neural activation that encompasses both glutamatergic and GABAergic neurons. We then deleted GLP-1R from each population and examined the behavioral and physiological outcomes at baseline and in response to short- and long-term liraglutide treatment in both lean and obese mouse models. We found that GLP-1Rs expressed in GABAergic neurons are dispensable for liraglutide-induced anorexia, weight loss, and neural network activation, whereas GLP-1Rs in glutamatergic neurons are required for these effects.
Research Design and Methods
Animals
lp1r
-flox (
),
vGAT
-Cre (
14
),
vGlut2
-Cre (
14
),
Glp1r
-Cre (
15
), and
L10
-GFP reporter (
16
) mice have been described previously (see
Supplementary Data
for breeding strategies). All studies were approved by the University of Michigan institutional animal care and use committee.
Immunohistochemistry
Pair-housed
vGAT
-GFP,
vGlut2
-GFP, and
Glp1r
-GFP (
= 7–8 per genotype and treatment, sexes combined) and singly housed male
Glp1r
-flox, vGAT
ΔGlp1r
, and vGlut2
ΔGlp1r
= 5 per genotype and treatment) were used for Fos analysis. Mice were fasted at 9:00
a.m.
and subcutaneously injected with either liraglutide (400 μg/kg; Novo Nordisk) or saline (10 mL/kg body weight) at 11:00
a.m
. At 1:00
p.m.
, mice were perfused and brains processed for immunostaining as previously described (
17
) (see
Supplementary Data
for antibodies used and protocol).
Microscopy and Image Analysis
Coordinates and landmarks for regions of interest were identified by counterstaining and the mouse brain atlas (
18
) (
Supplementary Table 1
). For each nucleus, counts from the left and right side were added, and then those from each coronal plane were averaged to yield one count per nucleus per mouse (see
Supplementary Data
regarding image acquisition and analysis).
Model Characterization
Knockdown of
Glp1r
in the hypothalami of vGAT
ΔGlp1r
and vGlut2
ΔGlp1r
mice was confirmed by semiquantitative real-time PCR (RT-PCR). Hypothalamic tissue was microdissected from male mice in the long-term liraglutide study (see below), with treatment groups collapsed (
= 13–14 per genotype) and processed and analyzed as previously described (
19
) (
Supplementary Data
).
For in situ hybridization (ISH),
Glp1r
-flox, vGAT
ΔGlp1r
, and vGlut2
ΔGlp1r
mice were decapitated under anesthesia; whole brains were dissected, flash-frozen in isopentane chilled on dry ice, and stored at −80°C. Sixteen-micrometer-thick cryostat coronal sections were thaw-mounted to slides and stored at −80°C. Slides were processed for ISH using RNAScope per the manufacturer’s protocol (Advanced Cell Diagnostics), and the multiplex fluorescent assay (320850) was used to visualize
Glp1r
(418851) and
Cre
(312281-C3) probes using Amp 4 Alt-A.
Animal Studies
Dosages of liraglutide were chosen on the basis of previous studies (
). For the longitudinal study, mice (
= 10 per sex and genotype) were singly housed at age 4 weeks, and body weight and food intake were monitored weekly. At age 13–15 weeks, mice were fasted at 10:00
a.m.
and then subcutaneously injected with either liraglutide (400 μg/kg) or saline at 5:00
p.m
. Preweighed food was given at 6:00
p.m.,
and food intake was measured 1, 2, 4, and 24 h later. Body weight was measured at the 24-h time point. One week later, all mice were given the opposite treatment (saline or liraglutide) in a crossover design, and the study was repeated. At age 15–17 weeks, mice were fasted at 9:00
a.m.,
and basal fasting blood glucose was measured at 1:00
p.m.
with a glucometer (Contour Next EZ; Bayer). Mice were then injected with liraglutide (400 μg/kg) or saline as above and blood glucose measured at 3:00
p.m
. The crossover treatment was performed 1 week later. At age 18 weeks, brains from the male
Glp1r
-flox, vGAT
ΔGlp1r
, and vGlut2
ΔGlp1r
mice were collected for Fos immunohistochemistry (IHC) analysis.
For the long-term liraglutide study, male
Glp1r
-flox, vGAT
ΔGlp1r
, and vGlut2
ΔGlp1r
mice (
= 6–8 per genotype and treatment) were weaned into group housing with standard rodent chow. At age 5 weeks, the food was switched to high-fat chow (D12451; Research Diets), and the mice were singly housed at age 9 weeks. At age 11 weeks, mice were randomly assigned to either the saline control or liraglutide group and subcutaneously injected once per day (5:00
p.m.
) for 2 weeks using a previously described ascending dosing schedule (
). Body weight and food intake were measured daily. On day 15, mice were decapitated under anesthesia and the hypothalamus was isolated, snap-frozen on dry ice, and stored at −80°C for semiquantitative RT-PCR analysis (see above). Gonadal and perirenal fat pads were removed and weighed. To assay conditioned taste avoidance (CTA), male and female
Glp1r
-flox, vGAT
ΔGlp1r
, and vGlut2
ΔGlp1r
mice (
= 8 per genotype and treatment) were singly housed at age 10–12 weeks, and the assay was performed as previously described (
20
) (
Supplementary Data
).
Statistics
Data are presented as mean ± SEM, and statistical analyses were performed with GraphPad Prism 7 software. Specific tests performed for each experiment, along with
values, are included in the figure legends. Post hoc tests after ANOVA were performed only if the interaction between the two variables was significant at
< 0.05.
Results
Liraglutide Activates Both GABAergic and Glutamatergic Neurons
To characterize the subtypes of neurons activated by liraglutide, we generated
vGAT
- and
vGlut2
-GFP mice to label GABAergic and glutamatergic neurons, respectively (
Fig. 1
). We then performed IHC for Fos, an early marker of neural activation, after liraglutide or saline injection. Representative images from brain regions known to be activated by GLP1RAs (
21
22
) show specific GFP expression in the GABAergic central amygdala (CeA) versus the glutamatergic basolateral amygdala and lateral parabrachial nucleus (lPBN) (
Fig. 1
and
). Liraglutide induced a significant increase in Fos+ cells in five regions: CeA, lPBN, bed nucleus of the stria terminalis (BNST), caudal nucleus of the solitary tract (cNTS), and area postrema (AP) (
Fig. 1
). No effect of liraglutide on Fos activation in the lateral septum, paraventricular thalamus, PVH, arcuate, ventromedial hypothalamus, lateral dorsal tegmental nucleus, or rostral NTS were found (
Supplementary Fig. 1
).
Figure 1.
Open in a new tab
Characterization of neuronal subtypes activated by liraglutide.
: Breeding schematic with genetic constructs used to generate
vGAT
-GFP and
vGlut2
-GFP mice.
and
: Representative images from the CeA (
) and lPBN (
), showing Fos IHC (red) after saline or liraglutide injection in
vGAT
-GFP (green) and
vGlut2
-GFP (green) neurons. Blue is DAPI. Scale bars = 100 μm. Regions of interest for quantification are highlighted by a dotted line.
: Quantification of Fos+ neurons per section in five regions. The proportion of Fos+ neurons positive for
vGAT
-GFP or
vGlut2
-GFP is indicated (
≥ 6). Data were analyzed by unpaired Student
test between drug treatments. White bars indicate GFP-negative neurons. ***
< 0.001. BLA, basolateral amygdala; CMV, cytomegalovirus; eGFP, enhanced green fluorescent protein; Lira, liraglutide; Sal, saline; scp, superior cerebellar peduncle.
The CeA and BNST are largely GABAergic regions, and 93.6 ± 1.2% and 88.9 ± 2.7%, respectively, of the Fos+ neurons in these regions were
vGAT
-GFP+. Conversely, in the glutamatergic lPBN, 95.4 ± 1.1% of Fos+ neurons were
vGlut2
-GFP+. The cNTS and AP were more heterogeneous in the expression of
vGlut2
- and
vGAT
-GFP. In the cNTS, 50.9 ± 3.5% of Fos+ cells were
vGAT
-GFP+, and 69.9 ± 2.8% were
vGlut2
-GFP+. In the AP, 45.4 ± 3.3% of Fos+ cells were
vGAT
-GFP+, and 93.2 ± 1.5% were
vGlut2
-GFP+. These combined percentages exceed 100, suggesting that a fraction of cNTS and AP neurons express both
vGAT
and
vGlut2
during development. Thus, peripheral liraglutide injection leads to activation of specific brain regions containing both GABAergic and glutamatergic neurons, consistent with a model of distributed GLP1RA action (
10
).
GLP-1R–Expressing Glutamatergic Neurons Mediate the Short-term Feeding Effects of Liraglutide
To test the role of GLP-1Rs expressed in GABAergic versus glutamatergic neurons in response to GLP1RAs, we generated mice lacking
Glp1r
in either
vGlut2
- or
vGAT
-expressing cells (
Fig. 2
). In the hypothalamus,
Glp1r
mRNA expression levels were 45.3 ± 5.1% and 50.2 ± 5.3% of controls in vGAT
ΔGlp1r
and vGlut2
ΔGlp1r
mice, respectively (
Fig. 2
). To confirm that this knockdown was cell-type specific, we performed double ISH for
Glp1r
and
Cre
transcripts in the liraglutide-responsive AP, which comprises both glutamatergic and GABAergic cell types.
Glp1r
-flox control mice had robust expression of
Glp1r
and no
Cre
throughout the AP. In vGAT
ΔGlp1r
mice, no overlap of
Cre
and
Glp1r
in the AP was found. In vGlut2
ΔGlp1r
mice, we observed many neurons expressing
Cre
, but
Glp1r
expression was absent throughout the AP (
Fig. 2
). The absence of
Glp1r
from the AP of vGlut2
ΔGlp1r
mice is consistent with transient developmental
vGlut2
expression across this region.
Figure 2.
Open in a new tab
Generation and validation of vGAT
ΔGlp1r
and vGlut2
ΔGlp1r
mice.
: Breeding schematic with genetic constructs.
: Semiquantitative RT-PCR of
Glp1r
in the hypothalamus of male mice (
≥ 13 per group). Data analyzed by one-way ANOVA. ***
< 0.001 by Tukey multiple comparisons test.
: Representative ISH images showing efficient knockdown of
Glp1r
(green) in cells containing
Cre
recombinase (red) in the AP. Blue is DAPI. Inset in left panels are shown at higher magnification in the right panels. Scale bars = 50 μm (left panels) and 10 μm (right panels).
vGAT
ΔGlp1r
and vGlut2
ΔGlp1r
mice exhibited normal body weight, food intake, and blood glucose at baseline (
Supplementary Fig. 2
). We then assessed the response of these genotypes to GLP1RA administration with regard to food intake, body weight, and blood glucose. After liraglutide injection, control and vGAT
ΔGlp1r
mice of both sexes decreased their 24-h food intake by 60–70% compared with saline injection. Liraglutide produced a significant but dramatically attenuated anorectic effect in vGlut2
ΔGlp1r
mice, with 24-h food intake decreasing by only 15–20% compared with saline treatment (
Fig. 3
). Of note, liraglutide-induced anorexia was delayed in vGlut2
ΔGlp1r
mice relative to vGAT
ΔGlp1r
and control mice (
Supplementary Fig. 3
), suggesting that some aspect of the effects of GLP1RAs may be mediated by non-
vGlut2
–expressing neurons. These results indicate that GLP-1Rs in glutamatergic neurons are required for the full anorectic effect of liraglutide.
Figure 3.
Open in a new tab
Short-term effects of liraglutide in vGAT
ΔGlp1r
and vGlut2
ΔGlp1r
chow-fed mice. Males and females are displayed separately (
and
) and combined (
). Change in total food intake (
) and body weight (
) 24 h after liraglutide or saline control injection. CTA test results (
) display the taste preference for saccharin after pairing with either saline, liraglutide, or lithium chloride (positive control).
≥ 10 (
and
) and
= 8 (
). Repeated-measures two-way ANOVA (
and
) or standard two-way ANOVA (
) was performed followed by Sidak (
and
) or Tukey (
) multiple comparisons test. Open symbols indicate saline treatment, partially filled symbols indicate lithium chloride treatment, and closed symbols indicate liraglutide treatment. *
< 0.05, **
< 0.01, ***
< 0.001.
Twenty-four hours after liraglutide injection, control and vGAT
ΔGlp1r
mice lost ∼5–6% of their body weight, whereas vGlut2
ΔGlp1r
mice maintained normal body weight (
Fig. 3
). Liraglutide lowered blood glucose equally in males of all three genotypes, but in females, only control and vGAT
ΔGlp1r
mice responded (
Supplementary Fig. 4
). Because liraglutide is known to cause visceral illness, we tested whether this effect requires GLP-1R in GABAergic or glutamatergic neurons by using a CTA assay. After learning to associate a novel taste (saccharin water) with lithium chloride (positive control), mice of all genotypes demonstrated a decreased preference for the saccharin water, indicating that the lithium chloride was aversive (
Fig. 3
). In contrast, liraglutide induced CTA in control and vGAT
ΔGlp1r
but not vGlut2
ΔGlp1r
mice, thus revealing that GLP-1Rs in glutamatergic neurons are also necessary for the visceral illness response to liraglutide.
Long-term Liraglutide-Induced Weight Loss Is Mediated by GLP-1R–Expressing Glutamatergic Neurons
To model the clinical use of liraglutide as an obesity therapy, we fed a second cohort of male
Glp1r
-flox, vGAT
ΔGlp1r
, and vGlut2
ΔGlp1r
mice a high-fat diet to induce obesity. After 6 weeks, all three genotypes had gained significant weight (15–20%) compared with genotype- and age-matched controls from the previous study, with no differences between groups (
Glp1r
-flox 29.5 ± 0.6 g, vGAT
ΔGlp1r
29.6 ± 0.6 g, vGlut2
ΔGlp1r
31.2 ± 0.7 g; not significant by one-way ANOVA).
Obese mice were then treated daily with liraglutide or saline for 14 days. As seen in the short-term studies,
Glp1r
-flox control and vGAT
ΔGlp1r
mice showed a decrease in food intake and body weight 24 h after liraglutide injection, whereas no effect was observed in vGlut2
ΔGlp1r
mice. Body weights of
Glp1r
-flox control and vGAT
ΔGlp1r
mice plateaued at ∼90% of original weight after 3 days of liraglutide treatment, whereas saline-treated mice steadily gained weight (
Fig. 4
). In contrast, liraglutide had no effect on weight gain in vGlut2
ΔGlp1r
mice. The sustained body weight loss in
Glp1r
-flox and vGAT
ΔGlp1r
mice was accompanied by a significant but transient drop in food intake that returned to normal after 4 days of treatment (
Fig. 4
). Food intake of vGlut2
ΔGlp1r
mice was not affected by liraglutide during the study. Long-term liraglutide reduced visceral fat pad weights in
Glp1r
-flox controls and vGAT
ΔGlp1r
mice but had no effect on fat pad weights in vGlut2
ΔGlp1r
mice (
Supplementary Fig. 5
). Together, these results suggest that GLP-1R–expressing glutamatergic neurons mediate both the short-term anorexia and the long-term weight loss effects of liraglutide.
Figure 4.
Open in a new tab
Long-term effects of liraglutide in vGAT
ΔGlp1r
and vGlut2
ΔGlp1r
high-fat diet–fed male mice. Body weight change from baseline (
) and daily food intake (
) during a 14-day treatment with once daily liraglutide or saline control injection. All mice were fed a 45% high-fat diet 6 weeks before and during the study (
≥ 6). Data were analyzed by repeated-measures two-way ANOVA followed by Dunnett multiple comparisons test. **
< 0.01, ***
< 0.001 at each time point compared with saline-treated controls of the same genotype.
Liraglutide Activates a Neuronal Network Through GLP-1R–Expressing Glutamatergic Neurons
To identify neural responses associated with these different behavioral phenotypes, we examined Fos IHC after saline and liraglutide treatment in male
Glp1r
-flox, vGAT
ΔGlp1r
, and vGlut2
ΔGlp1r
mice. In both
Glp1r
-flox controls and vGAT
ΔGlp1r
mice, liraglutide treatment significantly increased Fos+ cells in the same regions identified previously (i.e., CeA, BNST, lPBN, cNTS, AP). Somewhat surprisingly, Fos activation in all of these regions (both glutamatergic and GABAergic) was completely absent in vGlut2
ΔGlp1r
mice (
Fig. 5
). These data suggest that a population of glutamatergic GLP-1R–expressing neurons are activated directly by liraglutide and then engage a downstream neural network that is both glutamatergic and GABAergic to elicit potent physiological effects.
Figure 5.
Open in a new tab
Neuronal activation in vGAT
ΔGlp1r
and vGlut2
ΔGlp1r
mice after liraglutide injection.
and
: Representative images from the CeA (
) and lPBN (
) showing Fos IHC (brown) after saline or liraglutide injection. Sections were counterstained with hematoxylin. Scale bars = 100 μm.
: Quantification of Fos+ neurons in each of five brain regions (
≥ 3). Data were analyzed by two-way ANOVA followed by Tukey multiple comparisons test. Open symbols indicate saline treatment, and closed symbols indicate liraglutide treatment. **
< 0.01, ***
< 0.001.
Glp1r
–Expressing Neurons in the lPBN and AP Are Activated by Liraglutide
To identify which GLP-1R–expressing neurons are directly activated by liraglutide, we generated
Glp1r
-GFP mice (
Fig. 6
). The pattern of
Glp1r
-GFP expression across the brain generally agreed with that reported for
Glp1r
expression using other methods (
) (
Supplementary Fig. 6
).
Glp1r
-GFP mice were injected with saline or liraglutide for subsequent Fos analysis. Although
Glp1r
-GFP+ neurons were found in all five identified regions of interest, most were not activated by liraglutide. In the CeA, BNST, and cNTS, only 9.4 ± 1.1%, 10.7 ± 1.0%, and 9.4 ± 1.2%, respectively, of Fos+ neurons also expressed
Glp1r
-GFP. On the other hand, 28.6 ± 2.2% and 84.3 ± 1.3% of lPBN and AP Fos+ neurons, respectively, were
Glp1r
-GFP+ (
Fig. 6
and
). Thus, the lPBN and AP contained the highest percentage of liraglutide-activated Fos+ neurons that also expressed
Glp1r
-GFP, suggesting that glutamatergic neurons in these regions are critical for GLP1RA actions.
Figure 6.
Open in a new tab
Identification of liraglutide-activated neurons expressing
Glp1r
: Breeding schematic with genetic constructs used to generate
Glp1r
-GFP mice.
: Representative images from the CeA and AP showing Fos IHC (red) after saline or liraglutide injection in
Glp1r
-GFP (green) neurons. Blue is DAPI. Scale bars = 100 μm. Regions of interest for quantification are highlighted by a dotted line.
: Quantification of Fos+ neurons per section in each region. In each column, the proportion of Fos+ neurons positive for
Glp1r
-GFP is indicated in black (
≥ 6). Data were analyzed by unpaired Student
test between drug treatments. White bars indicate GFP-negative neurons. **
< 0.01, ***
< 0.001. CMV, cytomegalovirus; eGFP, enhanced green fluorescent protein; Lira, liraglutide; Sal, saline.
Discussion
Consistent with previously published data on other GLP1RAs (
21
24
), we found that peripheral liraglutide activates a rather limited network of cells in the BNST, CeA, lPBN, cNTS, and AP. Of the five liraglutide-activated nuclei that we identified, two (BNST, CeA) are primarily composed of
vGAT
-positive neurons, one (lPBN) almost exclusively is composed of
vGlut2
-positive neurons, and two (cNTS, AP) contain a mixture of both cell types. To test the role of these neuron groups in mediating the effects of liraglutide, we deleted
Glp1r
specifically in neurons expressing
vGAT
or
vGlut2
. We found that mice lacking GLP-1R in
vGlut2
-expressing neurons had a blunted anorectic response to liraglutide and did not lose body weight after short- or long-term treatment, whereas loss of
Glp1r
from
vGAT
-expressing neurons had no effect on liraglutide responsiveness. These data indicate that GLP-1Rs in
vGlut2
-expressing neurons are required for the majority of the anorectic and weight loss effects of liraglutide. Furthermore, we found that GLP1RA administration was associated with a distinct pattern of neuronal activation across both glutamatergic and GABAergic cell groups that depends on a direct effect of liraglutide on GLP-1R–expressing
vGlut2
+ neurons.
Nausea is a common early side effect of GLP1RAs in humans and may contribute to the initial appetite loss and subsequent weight loss (
25
). In rodents, drug-induced visceral illness can be inferred by the formation of a CTA to a novel taste paired with the drug (with the caveat that rats will sometimes exhibit CTA even to substances that they find rewarding, such as amphetamines [
26
]) and/or by pica (consumption of a nonnutritive clay after drug treatment). Long-term liraglutide treatment induced pica in rats only at the onset of treatment, mirroring reports of nausea in patients (
27
). Although well characterized in rats, the validity of the pica assay has been questioned in mice (
28
). In both rats and mice, peripheral administration of GLP1RAs also led to the formation of a CTA that is mediated by GLP-1R–expressing cells in the brain (
21
27
). Some evidence has suggested that the nausea and anorexia caused by GLP1RAs are achieved by separate and dissociable mechanisms. For example, in rats, direct administration of GLP1RAs into the fourth ventricle (
29
), the PVH (
30
), and the nucleus accumbens (
31
) reduces food intake without inducing CTA, although this may be dose dependent.
The CeA has been implicated as a neural mediator for the aversive effects of GLP1RAs because GLP1RA infusion into the CeA induced CTA without reducing food intake (
27
29
). The current results suggest that the CeA is not a direct site of action for peripherally administered liraglutide (although it could be a downstream target) because mice lacking
Glp1r
in the GABAergic CeA still formed a CTA to liraglutide. On the other hand, bona fide species differences between mice and rats, particularly pertaining to the GLP-1 system and CTA, have been identified previously (
32
). Thus, we cannot exclude the possibility that the CeA is an important direct site for GLP-1–induced aversion in rats but not in mice. Nevertheless, the current results suggest that although the sites of action may be separable, both the aversive and the anorectic effects of liraglutide require GLP-1R expression on
vGlut2
+ neurons.
Studies that used various methodological approaches in rats have implicated vagal GLP-1Rs in the anorectic effect of intraperitoneally administered GLP1RAs (
33
34
). However, rats subjected to subdiaphragmatic vagal afferent deafferentation responded normally to intravenous and subcutaneous liraglutide injection (
35
36
). Taken together, these studies suggest that the sites (peripheral vs. central) of action of GLP1RAs may differ depending on the route of drug administration as well as on the dosage. The current study was not specifically designed to test the role of vagal versus central GLP-1R. Because GLP-1R–expressing neurons in the nodose ganglion are glutamatergic (
15
) and would be deleted in vGlut2
ΔGlp1r
mice, a contribution of vagal afferent glutamatergic GLP-1R–expressing neurons in the anorectic effect of liraglutide cannot be fully excluded. However, mice lacking GLP-1Rs on vagal afferents responded normally to the same dose of subcutaneous liraglutide used in this study (
), underscoring the importance of central GLP-1R–expressing neurons in our paradigm.
GLP-1–expressing neurons in the brainstem are glutamatergic and project to the hypothalamus (
37
38
). Activation of brainstem GLP-1 neurons induces Fos expression in hypothalamic regions (
39
), suggesting that the hypothalamus mediates some of the effects of endogenous brainstem-derived GLP-1. However, the role of the hypothalamus in the physiological response to peripherally administered GLP1RAs is less clear. Some studies have found hypothalamic neuronal activation after short-term peripheral GLP1RA injection, whereas others, including the current study, have not (
21
22
40
). Mice with GLP-1R deleted from the majority of the hypothalamus (Nkx2.1-Cre), the PVH (Sim1-Cre), or the ventromedial nucleus (SF1-Cre) had normal anorectic responses to peripherally administered GLP1RAs (
11
13
). In addition, decerebrate rats, in which hindbrain-forebrain connectivity is severed, reduced their food intake comparably with control rats after peripheral GLP1RA administration (
41
). The current data support a model in which hypothalamic GLP-1Rs are not required for the anorectic effects of peripherally administered GLP1RAs.
In this study, mice lacking GLP-1R in either GABAergic or glutamatergic neurons did not differ from controls in body weight or food intake under basal conditions or when fed a high-fat diet, suggesting that GLP-1R in these neural populations is not necessary for normal appetite and body weight regulation. Indeed, whole-body
Glp1r
-knockout as well as pan-neuronal
Glp1r
-knockout mice exhibit normal food intake and body weight (
42
). However, the possibility of developmental compensation for loss of this receptor should not be overlooked. In rats, intracerebroventricular injection of a specific GLP-1R antagonist, exendin(9-39) has been shown to increase food intake in the short and long term, suggesting that neuronal GLP-1Rs contribute to normal feeding behavior (
43
44
). Site-specific manipulations, such as antagonist microinfusion or RNA interference–mediated
Glp1r
knockdown are further unraveling the roles of specific
Glp1r
-expressing populations in normal physiology (
45
47
). Future studies in mice should use site-specific viral delivery for Cre-mediated excision of
Glp1r
in adult mice or tamoxifen-inducible mouse strains to circumvent developmental compensation.
Endogenous GLP-1 can regulate feeding in the short term by signaling satiety as well as by inhibiting gastric emptying (
34
48
). Because synthetic GLP1RAs have been engineered for prolonged biological activity, it is plausible that the actions of GLP1RA will mimic those of endogenous GLP-1 in addition to inducing visceral illness. In the current study, control animals ate significantly less food within 1 h of liraglutide injection, and this effect was maintained for 24 h. Of note, vGlut2
ΔGlp1r
mice also exhibited a blunted food intake reduction at the 4- and 24-h time points after liraglutide administration, suggesting a role for nonglutamatergic GLP-1R–expressing cells in some aspect of the anorectic response. Future meal pattern analyses and gastric emptying studies will clarify the role of specific neuronal subsets in these physiological responses.
Long-term liraglutide administration decreased food intake for only 3 days in control and vGAT
ΔGlp1r
mice, whereas body weight was reduced throughout the study. Persistent weight reduction in the setting of transient anorexia suggests establishment of a new body weight set point. This phenomenon is seen with multiple weight loss regimens (e.g., lorcaserin [
49
], vertical sleeve gastrectomy [
50
]), and the mechanism underlying this shared response requires additional investigation. Future studies are needed to determine whether this transient anorexia reflects cellular desensitization or changes in neuronal response patterns after long-term liraglutide administration.
Liraglutide induces a characteristic pattern of Fos expression in a mixture of GABAergic and glutamatergic cell groups; moreover, this pattern requires GLP-1Rs on
vGlut2+
but not
vGAT+
neurons, which supports the hypothesis that a population of GLP-1R–expressing glutamatergic neurons serves as a gateway to transduce the signal of peripheral liraglutide into the brain. To identify the critical population of neurons, we treated
Glp1r
-GFP reporter mice with liraglutide and examined Fos activation specifically in
Glp1r
+ cells. We found that the greatest overlap of GLP-1R-GFP expression and Fos activation was within the AP and to a lesser extent in the lPBN, suggesting that glutamatergic cells in these two brain regions may be particularly important for liraglutide action.
The AP is a sensory circumventricular organ known to play important roles in autonomic output, nausea, and the response to emetic drugs (
51
). It is activated in response to peripheral administration of GLP1RAs (
24
52
), and liraglutide binds the AP in a GLP-1R–dependent manner (
35
). The current results suggest that the AP is an important site mediating the anorectic effects of GLP1RAs. In contrast, AP lesions in rats did not decrease the short-term anorectic or long-term weight loss effects of GLP1RAs (
35
53
). Although the apparent contradiction of these results with the current study might be explained by differences in drug, dose, species, and/or experimental paradigm, this discrepancy suggests the existence of both AP-dependent and AP-independent responses to peripheral GLP1RAs. The lPBN could be a candidate site for AP-independent actions of GLP1RAs because
) it is glutamatergic,
) it expresses GLP-1R and is activated by peripheral GLP1RAs (
23
24
), and
) direct lPBN infusion of exendin-4 decreases food intake and body weight (
46
). The NTS also has been identified as a potential site of action of GLP1RAs (
10
). Although the current study cannot completely exclude an NTS contribution, we found little liraglutide-induced Fos in NTS
Glp1r
-GFP cells. Furthermore, ISH revealed very few neurons expressing
Glp1r
mRNA in this region (data not shown). Determining the relative contribution of each of these regions to GLP1RA action will require future nucleus-specific manipulations.
In conclusion, we have used genetic mouse models to clarify the mechanisms whereby liraglutide decreases food intake and body weight. We found that short-term peripheral liraglutide injection activates several brain regions that comprise both GABAergic and glutamatergic neurons. By inactivating
Glp1r
in each population, we determined that liraglutide acts through GLP-1R exclusively expressed on glutamatergic,
vGlut2
-expressing neurons to activate a specific neuronal circuit, induce visceral illness, and reduce food intake and body weight in both the short and the long term. Moreover, GLP-1R expressed in GABAergic,
vGAT
-expressing neurons is not required for these effects. GLP-1R–expressing neurons in the AP and lPBN may be important direct targets through which peripherally administered liraglutide engages the CNS. Understanding the neural mechanisms by which liraglutide exerts its beneficial effects not only will help to elucidate its mechanism of action but also may reveal neural circuit components that might be exploited for more effective weight loss therapies.
Supplementary Material
Supplementary Data
DB171385SupplementaryData.pdf
(6.1MB, pdf)
Article Information
Acknowledgments.
The authors acknowledge the assistance of all the members of D.P.O.’s laboratory (University of Michigan), especially Korri Burnett and Allen Zhu, for mouse colony maintenance and genotyping.
Funding.
These studies were funded by the following National Institute of Diabetes and Digestive and Kidney Diseases grants: T32-DK-101357 (to J.M.A.), DK-082480 (to D.A.S.), DK-093848 and DK-107652 (to R.J.S.), DK-103703 (to S.D.L.), and DK-104999 (to D.P.O.).
Duality of Interest.
J.M.A., D.A.S., R.J.S., and D.P.O. received funding from Novo Nordisk. This work was supported in part by Novo Nordisk, which also supplied the liraglutide. The investigators also received support from Boehringer Ingelheim (to D.A.S. and R.J.S.), Ethicon Endo-Surgery (to D.A.S. and R.J.S.), MedImmune (to D.A.S., R.J.S., and D.P.O.), Sanofi (to R.J.S.), Janssen/Johnson & Johnson (to R.J.S.), Kallyope (to R.J.S.), and Zafgen (to R.J.S.). D.A.S. has served on a scientific advisory board for Novo Nordisk. R.J.S. has served on scientific advisory boards for Ethicon Endo-Surgery, Daiichi Sankyo, Janssen, Orexigen, Novartis, Nestlé, Takeda, Boehringer Ingelheim, Kallyope, Scohia, Sanofi, and Novo Nordisk. R.J.S. is also a paid speaker for Ethicon Endo-Surgery. No other potential conflicts of interest relevant to this article were reported.
Author Contributions.
J.M.A. and H.P. performed experiments and acquired the data. J.M.A., D.A.S., R.J.S., and D.P.O. designed the research studies. J.M.A. and D.P.O. analyzed and interpreted the data and wrote the manuscript. D.A.S., R.J.S., R.B.C., and S.D.L. provided reagents. D.A.S., R.J.S., and S.D.L. reviewed and edited the manuscript. D.P.O. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Prior Presentation.
Parts of this study were presented at the Keystone Symposia Conference, Copenhagen, Denmark, 9–13 May 2017.
Footnotes
This article contains Supplementary Data online at
References
1.
Holst JJ.
The physiology of glucagon-like peptide 1. Physiol Rev
2007;87:1409–1439
DOI
] [
PubMed
] [
Google Scholar
2.
Meier JJ.
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol
2012;8:728–742
DOI
] [
PubMed
] [
Google Scholar
3.
Pi-Sunyer X, Astrup A, Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group .
A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med
2015;373:11–22
DOI
] [
PubMed
] [
Google Scholar
4.
van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM.
Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes
2014;38:784–793
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
5.
van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M.
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol
2014;221:T1–T16
DOI
] [
PubMed
] [
Google Scholar
6.
Sisley S, Gutierrez-Aguilar R, Scott M, D’Alessio DA, Sandoval DA, Seeley RJ.
Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. J Clin Invest
2014;124:2456–2463
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
7.
Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR.
Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology
2011;152:3103–3112
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
8.
Merchenthaler I, Lane M, Shughrue P.
Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol
1999;403:261–280
DOI
] [
PubMed
] [
Google Scholar
9.
Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S.
Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab
2015;4:718–731
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
10.
Kanoski SE, Hayes MR, Skibicka KP.
GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol
2016;310:R885–R895
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
11.
Ghosal S, Packard AEB, Mahbod P, et al.
Disruption of glucagon-like peptide 1 signaling in Sim1 neurons reduces physiological and behavioral reactivity to acute and chronic stress. J Neurosci
2017;37:184–193
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
12.
Burmeister MA, Ayala JE, Smouse H, et al.
The hypothalamic glucagon-like peptide 1 receptor is sufficient but not necessary for the regulation of energy balance and glucose homeostasis in mice. Diabetes
2017;66:372–384
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
13.
Burmeister MA, Brown JD, Ayala JE, et al.
The glucagon-like peptide-1 receptor in the ventromedial hypothalamus reduces short-term food intake in male mice by regulating nutrient sensor activity. Am J Physiol Endocrinol Metab
2017;313:E651–E662
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
14.
Vong L, Ye C, Yang Z, Choi B, Chua S Jr., Lowell BB.
Leptin action on GABAergic neurons prevents obesity and reduces inhibitory tone to POMC neurons. Neuron
2011;71:142–154
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
15.
Williams EK, Chang RB, Strochlic DE, Umans BD, Lowell BB, Liberles SD.
Sensory neurons that detect stretch and nutrients in the digestive system. Cell
2016;166:209–221
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
16.
Krashes MJ, Shah BP, Madara JC, et al.
An excitatory paraventricular nucleus to AgRP neuron circuit that drives hunger. Nature
2014;507:238–242
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
17.
Sutton AK, Pei H, Burnett KH, Myers MG Jr., Rhodes CJ, Olson DP.
Control of food intake and energy expenditure by Nos1 neurons of the paraventricular hypothalamus. J Neurosci
2014;34:15306–15318
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
18.
Paxinos G, Franklin KBJ.
The Mouse Brain in Stereotaxic Coordinates. Amsterdam, Elsevier Academic Press, 2008
Google Scholar
19.
Adams JM, Otero-Corchon V, Hammond GL, Veldhuis JD, Qi N, Low MJ.
Somatostatin is essential for the sexual dimorphism of GH secretion, corticosteroid-binding globulin production, and corticosterone levels in mice. Endocrinology
2015;156:1052–1065
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
20.
Ding HK, Teixeira CM, Frankland PW.
Inactivation of the anterior cingulate cortex blocks expression of remote, but not recent, conditioned taste aversion memory. Learn Mem
2008;15:290–293
DOI
] [
PubMed
] [
Google Scholar
21.
Baraboi ED, St-Pierre DH, Shooner J, Timofeeva E, Richard D.
Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4. Am J Physiol Regul Integr Comp Physiol
2011;301:R1011–R1024
DOI
] [
PubMed
] [
Google Scholar
22.
Parker JA, McCullough KA, Field BCT, et al.
Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int J Obes
2013;37:1391–1398
DOI
] [
PubMed
] [
Google Scholar
23.
Yamamoto H, Lee CE, Marcus JN, et al.
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest
2002;110:43–52
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
24.
Baggio LL, Huang Q, Brown TJ, Drucker DJ.
A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes
2004;53:2492–2500
DOI
] [
PubMed
] [
Google Scholar
25.
Buse JB, Rosenstock J, Sesti G, et al.; LEAD-6 Study Group .
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet
2009;374:39–47
DOI
] [
PubMed
] [
Google Scholar
26.
Parker LA, Rana SA, Limebeer CL.
Conditioned nausea in rats: assessment by conditioned disgust reactions, rather than conditioned taste avoidance. Can J Exp Psychol
2008;62:198–209
DOI
] [
PubMed
] [
Google Scholar
27.
Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR.
The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology
2012;62:1916–1927
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
28.
Liu YL, Malik N, Sanger GJ, Friedman MI, Andrews PLR.
Pica--a model of nausea? Species differences in response to cisplatin. Physiol Behav
2005;85:271–277
DOI
] [
PubMed
] [
Google Scholar
29.
Kinzig KP, D’Alessio DA, Seeley RJ.
The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci
2002;22:10470–10476
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
30.
McMahon LR, Wellman PJ.
PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol
1998;274:R23–R29
DOI
] [
PubMed
] [
Google Scholar
31.
Dossat AM, Lilly N, Kay K, Williams DL.
Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. J Neurosci
2011;31:14453–14457
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
32.
Lachey JL, D’Alessio DA, Rinaman L, Elmquist JK, Drucker DJ, Seeley RJ.
The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology
2005;146:458–462
DOI
] [
PubMed
] [
Google Scholar
33.
Abbott CR, Monteiro M, Small CJ, et al.
The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res
2005;1044:127–131
DOI
] [
PubMed
] [
Google Scholar
34.
Krieger JP, Arnold M, Pettersen KG, Lossel P, Langhans W, Lee SJ.
Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia. Diabetes
2016;65:34–43
DOI
] [
PubMed
] [
Google Scholar
35.
Secher A, Jelsing J, Baquero AF, et al.
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest
2014;124:4473–4488
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
36.
Rüttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W.
Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology
2009;150:1174–1181
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
37.
Zheng H, Stornetta RL, Agassandian K, Rinaman L.
Glutamatergic phenotype of glucagon-like peptide 1 neurons in the caudal nucleus of the solitary tract in rats. Brain Struct Funct
2015;220:3011–3022
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
38.
Llewellyn-Smith IJ, Reimann F, Gribble FM, Trapp S.
Preproglucagon neurons project widely to autonomic control areas in the mouse brain. Neuroscience
2011;180:111–121
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
39.
Gaykema RP, Newmyer BA, Ottolini M, et al.
Activation of murine pre-proglucagon-producing neurons reduces food intake and body weight. J Clin Invest
2017;127:1031–1045
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
40.
Baggio LL, Huang Q, Brown TJ, Drucker DJ.
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology
2004;127:546–558
DOI
] [
PubMed
] [
Google Scholar
41.
Hayes MR, Skibicka KP, Grill HJ.
Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology
2008;149:4059–4068
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
42.
Scrocchi LA, Brown TJ, MaClusky N, et al.
Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med
1996;2:1254–1258
DOI
] [
PubMed
] [
Google Scholar
43.
Turton MD, O’Shea D, Gunn I, et al.
A role for glucagon-like peptide-1 in the central regulation of feeding. Nature
1996;379:69–72
DOI
] [
PubMed
] [
Google Scholar
44.
Meeran K, O’Shea D, Edwards CMB, et al.
Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology
1999;140:244–250
DOI
] [
PubMed
] [
Google Scholar
45.
Hayes MR, Bradley L, Grill HJ.
Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology
2009;150:2654–2659
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
46.
Alhadeff AL, Baird JP, Swick JC, Hayes MR, Grill HJ.
Glucagon-like peptide-1 receptor signaling in the lateral parabrachial nucleus contributes to the control of food intake and motivation to feed. Neuropsychopharmacology
2014;39:2233–2243
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
47.
Barrera JG, Jones KR, Herman JP, D’Alessio DA, Woods SC, Seeley RJ.
Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci
2011;31:3904–3913
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
48.
Williams DL, Baskin DG, Schwartz MW.
Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology
2009;150:1680–1687
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
49.
Thomsen WJ, Grottick AJ, Menzaghi F, et al.
Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther
2008;325:577–587
DOI
] [
PubMed
] [
Google Scholar
50.
Stefater MA, Pérez-Tilve D, Chambers AP, et al.
Sleeve gastrectomy induces loss of weight and fat mass in obese rats, but does not affect leptin sensitivity. Gastroenterology
2010;138:2426–2436, 2436.e1–2436.e3
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
51.
Price CJ, Hoyda TD, Ferguson AV.
The area postrema: a brain monitor and integrator of systemic autonomic state. Neuroscientist
2008;14:182–194
DOI
] [
PubMed
] [
Google Scholar
52.
Yamamoto H, Kishi T, Lee CE, et al.
Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci
2003;23:2939–2946
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
53.
Baraboi ED, Smith P, Ferguson AV, Richard D.
Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist. Am J Physiol Regul Integr Comp Physiol
2010;298:R1098–R1110
DOI
] [
PubMed
] [
Google Scholar
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplementary Data
DB171385SupplementaryData.pdf
(6.1MB, pdf)
ACTIONS
PERMALINK
RESOURCES
Cite
Download .nbib
.nbib
Format:
Add to Collections